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Background: The purpose of this study was to detect the serum microRNAs (miRNAs) that are differentially
expressed in cervical squamous cell carcinoma (SCC) patients and negative controls, with a focus on the miRNA
profiles of the patients before and after surgery. The aim of the study is to evaluate the potential of these miRNAs
as novel markers for the post-therapeutic monitoring of cervical SCC patients.
Results: A total of 765 serum miRNAs from 10 cervical SCC patients before surgery, 10 cervical SCC patients after
surgery, and 10 negative controls were profiled using a TaqMan MicroRNA Array. A set of selected differentially
expressed miRNAs were further analyzed in the patients at different perioperative periods, including preoperative,
1 week postoperative, and one month postoperative. The results showed that several serum miRNAs were
differentially expressed in the cervical SCC patients compared with the negative controls, including miR-646,
miR-141* and miR-542-3p. More importantly, we found that levels of specific serum miRNAs were deregulated in
the pre- and postoperative stages, and these miRNAs could be useful for post-therapeutic monitoring of disease
progression. Finally, we depicted a regulatory network of differentially expressed serum miRNAs, and many possible
target genes were predicted in the estrogen-mediated signal pathways, supporting the hypothesis that cervical
SCC is a hormone-associated gynecological disease.
Conclusions: Our study demonstrated that the circulating miRNAs miR-646, miR-141* and miR-542-3p could
potentially serve as non-invasive biomarkers for cervical SCC. The levels of these specific miRNAs might be useful
for the post-therapeutic monitoring of disease progression. This is the first report showing that circulating miRNAs
could serve as biomarkers for the therapeutic intervention of cervical SCC.
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Cervical squamous cell carcinoma (cervical SCC) is a
common cervical cancer type that is closely correlated
with high-risk human papillomavirus (HPV) infection [1,
2]. Cervical SCC is the third most malignant carcinoma
that affects women's health and is the leading cause* Correspondence: lsscyq@mail.sysu.edu.cn; dr-hong-clinic@163.com
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stated.of death from cancer in women worldwide. Due to
standardized screening of cervical cancer, the morbidity and
mortality rates of cervical SCC have decreased [3]. However,
due to patients’ resistance to therapeutic interventions, the
annual number of cervical cancer deaths has continued to
rise and is more prevalent in developing countries [4].
Therefore, an increased understanding of the molecular
mechanisms and the screening of predictive biomarkers for
cervical SCC progression and metastasis is necessary.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that are approximately 22 nucleotides in length and
regulate gene expression post-transcriptionally through
translational repression or transcript cleavage [5, 6]. Manytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Table 1 Clinicopathologic Characteristics of CSCC* patients


























*CSCC - Cervical Squamous Cell Carcinoma.
**FIGO - International Federation of Gynecology and Obsterics.
***LNM - Lymph Node Metastasis.
****LVSI - Lymph Vascular Space Invasion.
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cesses [5, 6], and the dysregulation of these events can lead
to the occurrence of a number of diseases, such as lung can-
cer [7], prostate cancer [8], colorectal tumor [9], leukemia
[10], and cervical cancer [11]. The miRNA research in the
past 20 years, including the development of sensitive mo-
lecular detection techniques in the last 5 years, has allowed
researchers to investigate miRNAs in circulation and in
body fluids, such as serum [12], human whole saliva [13],
and urine [14], initiating a new era of disease research.
A pilot study by Roth et al. demonstrated that the
concentration of miR-155 in sera can be a significant
index to distinguish patients with primary breast cancer
from healthy women, and the levels of circulating miR-34
could indicate the disease progression stage [15]. A
growing number of investigations of circulating miRNAs
have revealed the remarkable potential value of circulating
miRNAs for the diagnosis and prognosis of diseases, espe-
cially cancer [16-19]. Our previous study also showed that
circulating miR-122, miR-145*, miR-199a and miR-542-3p
could potentially act as noninvasive biomarkers for endo-
metriosis [20]. Although circulating miRNAs have been
described as important non-invasive biomarkers with high
sensitivity and specificity in many other diseases, the study
of circulating miRNA in cervical cancer is limited [21, 22],
and no studies have reported miRNA expression patterns
in cervical cancer patients before and after surgery.
In this study, we screened the differentially expressed
miRNAs in the serum of cervical cancer patients, with
a focus on the miRNA profiling before and after surgery.
The aim of the study is to screen for the predictive
biomarkers that could be useful for post-therapeutic
monitoring of cervical SCC patients.
Material and Methods
Patient and sample material
Serum samples and clinicopathologic data were collected
from 10 primary cervical SCC patients who underwent
radical hysterectomies with pelvic lymph node dissections
in 2008 in the Department of Gynecology at Hainan
Provincial People’s Hospital (Haikou, China). The mean age
was 51.0 years (range, 34-78 years). Of these 10 patients, no
patients received chemotherapy or radiotherapy prior to
surgery. Blood samples were collected before surgery, and
then one week and one month after surgery. According to
the 5-year follow-up, 5 of the 10 patients were still alive,
but the other patients had poor prognoses.
The clinicopathologic data are shown in Table 1. The
control serum samples were collected from 15 volunteers
who sought diagnostic laparoscopy due to infertility in
the Department of Gynecology, Sun Yat-sen Memorial
Hospital (Guangzhou, China) in 2011. All volunteers were
diagnosed with fallopian tube disease with neither cervical
intraepithelial neoplasia nor HPV infection. The mean ageof the volunteers was 28.8 years (range 24-34 years). None
of the 15 women were treated with hormone therapy in the
3 months before the operation, and serum samples were
taken 1-3 days prior to the laparoscopic procedure. All
patients provided informed consent, and the study
was approved by the ethics committees of Sun Yat-sen
University and Hainan Provincial People’s Hospital.
Serum harvested and RNA extraction
Fasting blood samples were collected from all donors
and were separated into serum and cellular components
within 1 h at 3000 rpm at 4°C for 10 minutes after being
left to clot at room temperature. The sera were stored
at -80°C until RNA extraction. Isolation of total RNA
from 1 ml of serum was conducted according to the
manufacturer’s instructions of the mirVana PARIS Kit
(Ambion, Austin, TX). The RNA samples were then frozen
at -80°C.
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Using the Taq-Man miRNA array, we initially profiled 768
miRNAs from two pooled samples, including a pool of 10
cervical SCC samples and a pool of 15 negative controls.
To quantify the accurate amounts of miRNAs in the serum
of samples, we reverse transcribed 50 ng total RNA for
each sample using the ReverTra Ace qPCR RT Kit
(Toyobo, Osaka, Japan). The miRNA levels were deter-
mined in triplicate using SYBR Premix Ex Taq II-based
(Takara, Kyoto, Japan) quantitative real-time PCR with
Roche Light Cycler 480II (Roche, Switzerland). U6 small
nuclear RNA, a common internal control used in studies
quantifying circulating miRNAs, was used to normalize the
relative expression of miRNAs [23, 24].
Statistical analysis
GraphPad Prism software (version 5.0) was used to perform
the statistical analyses and generate figures. The heat map
was analyzed using Cluster 3.0 and TreeView software.
Cytoscape (version 3.0.1) was used to network the miRNAs
and the target genes. The final figures were generated using
Adobe Illustrator CS5. We determined the significance of
the differentially expressed miRNA levels between two
groups (patient and negative control) using Fisher’s exact
test and the Mann–Whitney U-test, while the related
samples (pre- and postoperative) were analyzed using
Wilcoxon signed rank test and three groups and multiple
comparisons using the Kruskal-Wallis test and the least
significant difference test after ranking the relative
expression, respectively. In this study, the P < 0.05 with
two tails was considered statistically significant.
Results
A significant number of miRNAs are present in serums of
patients with cervical SCC
To identify the potential clinical applications of circulating
miRNAs, TaqMan arrays were used to screen miRNAs
from two pools of serum samples including 10 cervical
SCC patients and 10 healthy women. The results showed
that the levels of 291 of the 338 detectible circulating
miRNAs were more than two-fold change in the cervical
SCC serum samples than the negative control serums
(Additional file 1: Table S1). We identified 40 upregulated
and 26 downregulated miRNAs that showed differential
expression profiles greater than ten-fold in the pooled
cervical SCC serum sample compared with the negative
control (Additional file 2: Table S2). These miRNAs
include miR-21-5p [25], miR-143-3p [25] and miR-214-3p
[26], which has been reported as being related to cervical
SCC. MiR-646 was the most abundant miRNA species in
the cervical SCC serum sample, while miR-508 was the
most downregulated miRNA.
To confirm the accuracy of the genome-wide screening,
5 of the most dysregulated miRNAs were selected for avalidation sample set (10 for cervical SCC and 15 for
negative control). Among the selected miRNAs, 3 of
the 5 were significantly different in the cervical SCC
serum samples when compared to the control group:
miR-646 (upregulated, p < 0.05, Figure 1A), miR-141*
(downregulated, p < 0.001, Figure 1B) and miR-542-3p
(down-regulated, p < 0.01, Figure 1C). These results sug-
gested that specific serum miRNAs could serve as inform-
ative biomarkers for the cervical SCC, though a larger
cohort of samples is required to validate this observation.
Differentially expressed miRNAs in the serum of cervical
SCC patients before and after surgery
We next asked if the miRNAs were different in the serum
of the patients before and after surgery. To evaluate the
expression of serum miRNAs in the perioperative periods,
we further profiled miRNA spectra from pools of 10
cervical SCC serum samples before surgery and 10 serum
samples after surgery. We identified 765 miRNAs during
this analysis process. In this profile, the expression levels of
133 miRNAs were found to be increased more than
two-fold in the serum 1 week after surgery compared
to that before operation, while 81 microRNAs were
decreased after surgery (Additional file 3: Table S3).
Figure 2 illustrates the most differentially expressed
miRNAs in the whole serum sample among the negative
control and the cervical SCC patient before and after
surgery. Unsupervised hierarchical clustering was used
to separate the samples and miRNAs into different
groups. Additional file 4: Table S4 exhibited a greater
than ten-fold change between the cervical SCC pooled
serum samples before and after surgery, including the
most abundant miRNA, miR-1243, and the most down-
regulated miRNA, miR-646. In the validation test, 9
differentially expressed miRNAs were chosen for further
study with the 10 matched-pair serum samples before and
after surgery. Among the selected miRNAs, 5 of the 9
could clearly distinguish cervical SCC serum samples
after surgery with high confidence (p < 0.05): miR-646
(Figure 3A), miR-143-3p (Figure 3B), miR-21-5p (Figure 3C),
miR-200a-3p (Figure 3D) and miR-214-3p (Figure 3E).
Differentially expressed miRNAs in the serum of cervical
SCC patients before and after surgery suggest that the
expression levels of serum miRNAs have potential to serve
as novel biomarkers for monitoring the therapy outcome
during the perioperative period for cervical SCC.
Levels of specific miRNAs might be used for
post-therapeutic monitoring of the cancer in progression
The observation above indicated that the serum miRNAs
were differentially expressed in patients before and after
surgery. To further investigate if levels of specific circulat-
ing miRNAs could be used to monitor the therapy outcome
or post-therapeutic progression, eight miRNAs (miR-132,
Figure 1 Differentially expressed miRNAs in the serum of cervical SCC patients and control samples. The miRNA expression levels in
serum from cervical SCC patients (n = 10) and negative controls (n = 15). The expression profiles of miR-646 (A) were significantly higher in cervical
SCC patients (P < 0.05), whereas those of miR-141* (B), and miR-542-3p (C) were lower in cervical SCC patients (P < 0.001). The indicated P values were
determined by a two-tailed Mann–Whitney U-test, * p < 0.05, *** p < 0.001.
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miR-200a-3p, and miR-646) were used to perform the
subsequent qRT-PCR validation in the different periopera-
tive periods of the same patients, including preoperative, 1
week postoperative, and one month postoperative. These
miRNAs were selected based on the highest difference in
expression or whether they had been previously reported
to function in cervical SCC.
Four miRNAs (miR-132 (p < 0.05), Figure 4A; miR-
181c (p < 0.05), Figure 4B; miR-15a (p < 0.01), Figure 4C;
and miR-370 (p < 0.01), Figure 4F) were found to sig-
nificantly decrease one month after surgery compared to
the preoperative levels. Other three miRNAs (miR-143-3p,
Figure 4D; miR-21-5p, Figure 4E; and miR-200a-3p,
Figure 4G) showed significant differential expression
levels between preoperative and postoperative patients
(p < 0.01). Notably, among the cervical SCC patient serum
samples, the relative concentration of miR-646 (Figure 4H)
was found to steadily decrease 1 week and one month
after surgery compared to the preoperative samples. These
results suggest that the levels of specific circulating
miRNAs could be used for monitoring the therapy
outcome or post-therapeutic monitoring of cervical
SCC in progression. Further studies with larger cohort of
clinical samples, especially different therapeutic period
samples are necessary.
Regulation network of differentially expressed serum
miRNAs in the enriched pathways and processes of
cervical SCC
The variation in serum miRNA expression levels before and
after surgery suggested an association between miRNAs
and the key proteins underlying mechanisms related to the
therapy. To better understand the possible biological
pathways that the serum miRNAs might be involved in,
we constructed a miRNA-mRNA network to search themiRNA target genes that might function in the cervical
SCC process. Analysis using the StarBase database [27],
the Database for Annotation, Visualization and Integrated
Discovery (DAVID) [28], and a Fisher exact test uncovered
the enriched biological pathways, including cell cycle
and proliferation (p < 0.001, 57 genes); hormone stimulus
response (p < 0.001, 18 genes); cell migration regulation
(p < 0.02, 31 genes); apoptosis (p < 0.03, 20 genes); and
stem cell related pathways (p < 0.05, 8 genes). A global
network of the selected miRNAs and their target
genes (or potential target mRNAs) is depicted in Figure 5.
All of genes possess more than 5 edges, and many possible
target genes were predicted in the estrogen-mediated
signal pathways. For example, insulin-like growth factor 1
(IGF1R) shares important signaling cascades with estrogen
receptor [29], while forkhead box O1 (FOXO1) is involved
in the estrogen mediated E2/PI3K/Akt/FOXO1 pathway
[30]. It has been reported that cervical SCC is a hormone-
associated gynecological disease [31].
Notably, a number of miRNAs were related to chemo-
therapy drug responses or regulation of cell adhesion
and migration (Figure 5, red and purple box indicated).
For instance, miR-143-3p, miR-181c-5p, miR-200a-3p,
miR-21-5p, and miR-370-3p were predicted to target
metallopeptidase domain 9 (ADAM9). ADAM9 has
been reported to be involved in the biological pathway
of chemotherapy [32] and involved in the biological
processes such as cell adhesion and migration in the
cervical SCC [33]. Another example is BCL2, which
contains the reverse complements to miR-15a-5p and
miR-181c in the 3’UTR, responds to anthracycline
combination (ATC) chemotherapy [34], and plays an
important role in cervical cancer progression [35]. These
results showed a probable link between circulating
miRNAs and estrogen-associated with the cervical SCC as
well as chemotherapy.
Figure 2 The heat map displays the top 80 microRNAs with the most differential expression levels in the control and the patients
before and after surgery. The average level for each of the 3 miRNA serum samples was set as 1. The fold changes of individual miRNAs of the
control and before or after surgery against the average miRNA level were analyzed by unsupervised hierarchical clustering.
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Figure 3 The differential expressed miRNAs in the matched serum samples from cervical SCC patients before and after surgery.
MiR-646 (A) is expressed a higher level in the serum of cervical SCC patients after surgery than that before surgery, whereas, miR-143-3p
(B), miR-21-5p (C), miR-200a-3p (D), and miR-214-3p (E) are expressed a lower level postoperatively.
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Finding a non-traumatic biomarker for predicting the
prognosis of cancer and monitoring the outcome of
therapy has a significant importance to cancer research.
Several factors have been reported to be predictive
biomarkers for monitoring of cervical cancer recurrence,
such as squamous cell carcinoma antigen (SCCA) [36],
carbohydrate antigen 125 (CA125) [37], vascular endothe-
lial growth factor (VEGF) [38] among others, but these
markers have low sensitivity and specificity. HPV testing
was also reported as a well accepted maker for IVD
of cervical SCC worldwide. However, the recent progress
has proposed that the efficiency of HPV DNA/RNA testing
is dependent largely on the sampling method and cervicalcancer screening using cytologic testing alone or together
with HPV DNA/RNA testing is less-frequent [39].
Therefore, developing novel biomarkers for clinical diagno-
sis and therapeutic intervention require further research.
While miRNA testing is based on serum, which is more
stable and have less influence during sampling. In this
study, we screen the differentially expressed miRNAs in
the serum of cervical SCC patients, with a focus on the
miRNA profiling before and after surgery. Notably, a
number of serum miRNAs differentially expressed in the
cervical SCC compared with the negative control, including
miR-646, miR-141* and miR-542-3p. More importantly, we
revealed that the levels of specific serum miRNAs that were
differentially expressed in the patients before and after
Figure 4 The expression levels of specific circulating miRNAs were significantly different between the serum samples at the
preoperative, 1 week or one month after surgery. MiR-132 (A) and miR-181c (B) was decreased significantly one month after surgery compared
to the preoperative level; no significant difference between the other two groups. The expression levels of miR-15a (C) and miR-370 (F) were
significantly decreased 1 month after surgery compared to the preoperative levels and 1-week postoperative levels; no significant differences
were observed between the preoperative and one week postoperative levels. The levels of miR-143-3p (D) and miR-21-5p (E) were significantly
decreased 1 week and 1 month after surgery compared with the preoperative levels; no significant differences between the of one week
postoperative and one month postoperative levels were. The expression levels of miR-200a-3p (G) was decreased significantly 1 week
after surgery compared to the preoperative levels, but increased significantly when compared to 1 month postoperative levels. The expression levels of
miR-646 (H) were significantly different between all three time points.
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with larger samples. This study is the first report on
circulation miRNAs in patients before and after surgery.
Finally, we also depicted the regulation network of
differentially expressed serum miRNAs and discussed
the possible functions in which these miRNAs might be
involved, which could help us to understand the molecu-
lar mechanisms underlying the high tumorigenicity of the
cancer and to identify new therapeutic strategies.
In recent years, a number of studies have indicated
that the presence of altered miRNA profiles in the
serum for several cancer types and other diseases (15-20),suggesting that circulating miRNAs are potential novel
biomarkers. Several studies have also shown that miRNAs
may be useful in clinical management during the
perioperative period. For instance, Ng et al. [40] found
that the expression levels of serum miR-17-3p and miR-92
decrease postoperatively compared with the preoperative
period in colorectal cancer patients. Similar results have
been discovered in breast cancer patients [17]; the pre-
operative expression levels of miR-195 were significantly
higher than those of healthy controls but decreased 2
weeks after surgery. Peng Qi et al. [41] showed that the
expression level of miR-122 continues to decrease in
Figure 5 Network of microRNAs and their target genes associated with the biological pathway and the diagnosis of cervical SCC.
(Node Shape: triangle for microRNA, square for target gene; edges for relationship.)
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infection compared with preoperative and healthy
people. MiR-218 was reported to be associated with
cervical adenocarcinoma and lymphatic node metasta-
sis and was reduced in the plasma compared withhealthy people [21]. Together with the results of this
study, it could be suggested that circulating miRNAs
might be useful biomarkers for monitoring the ther-
apy outcome or post-therapeutic monitoring of disease
progression.
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affecting women's health and leading death worldwide, and
understanding the molecular mechanisms underlying the
high tumorigenicity of this cancer is necessary. Previous
research has demonstrated that some specific miRNAs
contribute to the pathogenesis and process of cervical
SCC. For example, Martinez et al. [11] illustrated that
miR-218 is reduced by HPV type 16 (HPV-16) infection
and mediates the expression level of LAMB3, which
has provided a better understanding of the molecular
mechanisms involved in cervical carcinogenesis.
In our work, a miRNA-mRNA predictive targeting
network has been developed to search for the critical
genes that function in the biological processes of cervical
SCC. From a large amount of genes in the network, we
found a total of 72 genes in mainstream biological
pathways that are commonly targeted by 5 or more
specific miRNAs. Interestingly, the selected miRNA
target genes were predicted to affect main biological
processes such as hormone-mediated signal pathways
and chemotherapy responses. For example, BCL2, which
responds to anthracycline combination (ATC) chemother-
apy, is the target of miR-15a-5p and miR-181c and was
found in the cervical SCC regulatory network. The results
suggest that the miRNAs and their target genes might not
only serve as novel diagnostic biomarkers but also as new
therapeutic targets.
In conclusion, our study demonstrated that the circulat-
ing miRNAs could potentially serve as non-invasive
biomarkers for cervical SCC. MiR-646, miR-141* and
miR-542-3p levels were significantly different between
cervical SCC serum samples and the control group. More
importantly, the expression levels of miR-21, miR-200a,
miR-143, miR-15a, miR-181c, miR-646, miR-132 and
miR-370 in the serum can, to some extent, be used
as biomarkers to monitor therapeutic efficacy. Further
investigation with a larger cohort of samples is required to
validate these observations. This study is the first report
that circulating miRNAs could serve as biomarkers for the
therapeutic intervention of cervical SCC.Additional files
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